{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:43:24Z","timestamp":1790631804116,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/1008-682x.125903","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T07:53:01Z","timestamp":1398844381000},"page":"372","source":"Crossref","is-referenced-by-count":20,"title":["Anti-angiogenesis in prostate cancer: knocked down but not out"],"prefix":"10.4103","volume":"16","author":[{"given":"Yu-Ning","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Bilusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.125903-1","first-page":"1029","volume-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"key":"key-10.4103\/1008-682X.125903-2","first-page":"353","volume-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"key-10.4103\/1008-682X.125903-3","first-page":"1742\u221257","volume-title":"Metastasis: recent discoveries and novel treatment strategies","author":"Eccles","year":"2007","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.125903-4","first-page":"1","volume-title":"Angiogenesis","author":"Folkman","year":"2006","journal-title":"Ann Rev Med"},{"key":"key-10.4103\/1008-682X.125903-5","first-page":"1182","volume-title":"Tumor angiogenesis: therapeutic implications","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.125903-6","first-page":"27","volume-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"key-10.4103\/1008-682X.125903-7","first-page":"389","volume-title":"Mechanisms of angiogenesis and arteriogenesis","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"key-10.4103\/1008-682X.125903-8","first-page":"753","volume-title":"Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions","author":"Morabito","year":"2006","journal-title":"Oncologist"},{"key":"key-10.4103\/1008-682X.125903-9","first-page":"2329","volume-title":"Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells","author":"Ferrer","year":"1997","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.125903-10","first-page":"523","volume-title":"Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer","author":"Duque","year":"1999","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.125903-11","first-page":"1932","volume-title":"Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480","author":"George","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-12","first-page":"479","volume-title":"Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma","author":"Gettman","year":"1999","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.125903-13","first-page":"401","volume-title":"Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma","author":"Weidner","year":"1993","journal-title":"Am J Pathol"},{"key":"key-10.4103\/1008-682X.125903-14","first-page":"821","volume-title":"Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer","author":"Cvetkovic","year":"2001","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.125903-15","first-page":"1936","volume-title":"Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue","author":"Du","year":"2003","journal-title":"Chin Med J"},{"key":"key-10.4103\/1008-682X.125903-16","first-page":"485","volume-title":"Vascular endothelial growth factor and angiopoietin are required for prostate regeneration","author":"Wang","year":"2007","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.125903-17","first-page":"41","volume-title":"The value of progression-free survival to patients with advanced-stage cancer","author":"Fallowfield","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-18","first-page":"3461","volume-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-19","first-page":"1148","volume-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-20","first-page":"2766","volume-title":"Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer","author":"Halabi","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-21","first-page":"3965","volume-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-22","first-page":"411","volume-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.125903-23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1201\/b15803","volume-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase ii randomized discontinuation trial","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-24","first-page":"209","volume-title":"A phase II clinical trial of sorafenib in androgen-independent prostate cancer","author":"Dahut","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-25","first-page":"65","volume-title":"A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer","author":"Reese","year":"2001","journal-title":"Prostate J"},{"key":"key-10.4103\/1008-682X.125903-26","first-page":"526","volume-title":"A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006","author":"Picus","year":"2011","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.125903-27","first-page":"1534","volume-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-28","first-page":"242","volume-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-29","first-page":"29","volume-title":"ML18147 Study Investigators.Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.125903-30","first-page":"1636","volume-title":"Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer","author":"Aragon-Ching","year":"2009","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.125903-31","first-page":"1480","volume-title":"A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV","author":"Steinbild","year":"2007","journal-title":"Br J Cancer"},{"key":"key-10.4103\/1008-682X.125903-32","first-page":"746","volume-title":"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer","author":"Chi","year":"2008","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.125903-33","first-page":"688","volume-title":"Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1\/2 clinical trial","author":"Zurita","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.125903-34","first-page":"76","volume-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer","author":"Michaelson","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-35","first-page":"11393","volume-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"key-10.4103\/1008-682X.125903-36","first-page":"3499","volume-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","author":"Van","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-37","first-page":"1743","volume-title":"Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors","author":"Isambert","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-38","first-page":"760","volume-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.125903-39","first-page":"4192","volume-title":"Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice","author":"Ng","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-40","first-page":"822","volume-title":"An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer","author":"Drake","year":"2003","journal-title":"Br J Cancer"},{"key":"key-10.4103\/1008-682X.125903-41","first-page":"2532","volume-title":"Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer","author":"Dahut","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-42","first-page":"5269","volume-title":"Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I\/II double-blinded, randomized study","author":"Keizman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-43","first-page":"241","volume-title":"Aphase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer","author":"Tohnya","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"key-10.4103\/1008-682X.125903-44","doi-asserted-by":"crossref","unstructured":"Petrylak DP, Fizazi K, Sternberg C, et al. Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial. 2012 ESMO Congress. Abstract LBA24.","DOI":"10.1016\/S0923-7534(20)34329-5"},{"key":"key-10.4103\/1008-682X.125903-45","first-page":"2070","volume-title":"Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer","author":"Ning","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-46","first-page":"293","volume-title":"c-met proto-oncogene expression in benign and malignant human prostate tissues","author":"Pisters","year":"1995","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.125903-47","first-page":"3088","volume-title":"A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases","author":"Lee","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-48","first-page":"1768","volume-title":"Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer","author":"Isaacs","year":"2006","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.125903-49","first-page":"4022","volume-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.125903-50","first-page":"4389","volume-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-51","first-page":"445","volume-title":"Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)","author":"Ryan","year":"2007","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/1008-682X.125903-52","first-page":"1269","volume-title":"Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer","author":"Dahut","year":"2013","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.125903-53","first-page":"4820","volume-title":"A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer","author":"Rosen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.125903-54","first-page":"3557","volume-title":"Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors","author":"Herbst","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:23:42Z","timestamp":1786649022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.125903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"alternative-id":["125903"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.125903","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}